Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase β and the IGF-I receptor to regulate IGF-I-stimulated signaling

Molecular and Cellular Biology

Volumn 32, Issue 20, 2012, Pages 4116-4130

  Shen, Xinchun ^a   Xi, Gang ^a   Maile, Laura A ^a   Wai, Christine ^a   Rosen, Clifford J ^b   Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Maine Medical Center Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE BETA; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVATION; GENE SILENCING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR I; MICE; MUSCLE, SMOOTH, VASCULAR; PTEN PHOSPHOHYDROLASE; RECEPTOR, IGF TYPE 1; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 5; SERINE; SIGNAL TRANSDUCTION;

MUS;

EID: 84868688906     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01011-12     Document Type: Article

References (54)

1. Abbott KL, Matthews RT, Pierce M. 2008. Receptor tyrosine phosphatase beta (RPTPbeta) activity and signaling are attenuated by glycosylation and subsequent cell surface galectin-1 binding. J. Biol. Chem. 283:33026- 33035.
2. Azar WJ, et al. 2011. IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Endocrinology 152:3332-3342.
3. Bilwes AM, den Hertog J, Hunter T, Noel JP. 1996. Structural basis for inhibition of receptor protein-tyrosine phosphatase-alpha by dimerization. Nature 382:555-559.
4. Bourner MJ, et al. 1992. Cloning and sequence determination of bovine insulin-like growth factor binding protein-2 (IGFBP-2): comparison of its structural and functional properties with IGFBP-1. J. Cell. Biochem. 48: 215-226.
5. Brisbin S, et al. 2009. A role for C. elegans Eph RTK signaling in PTEN regulation. Dev. Cell 17:459-469.
6. Cohick WS, Clemmons DR. 1991. Regulation of insulin-like growth factor binding protein synthesis and secretion in a bovine epithelial cell line. Endocrinology 129:1347-1354.
7. Coles CH, et al. 2011. Proteoglycan-specific molecular switch for RPTPsigma clustering and neuronal extension. Science 332:484-488.
8. Conover CA, Khosla S. 2003. Role of extracellular matrix in insulin-like growth factor (IGF) binding protein-2 regulation of IGF-II action in normal human osteoblasts. Growth Horm. IGF Res. 13:328 -335.
9. DeMambro VE, et al. 2008. Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology 149:2051- 2061.
10. DeMambro VE, et al. 2012. Insulin-like growth factor binding protein-2 is required for osteoclast differentiation. J. Bone Miner. Res. 27:390-400. (Erratum, 27:1436.).
11. Deuel TF, Zhang N, Yeh HJ, Silos-Santiago I, Wang ZY. 2002. Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway. Arch. Biochem. Biophys. 397:162-171.
12. Duan C, Ding J, Li Q, Tsai W, Pozios K. 1999. Insulin-like growth factor binding protein 2 is a growth inhibitory protein conserved in zebrafish. Proc. Natl. Acad. Sci. U. S. A. 96:15274 -15279.
13. Firth SM, Baxter RC. 2002. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23:824-854.
14. Hamidouche Z, Fromigue O, Ringe J, Haupl T, Marie PJ. 2010. Crosstalks between integrin alpha 5 and IGF2/IGFBP2 signalling trigger human bone marrow-derived mesenchymal stromal osteogenic differentiation. BMC Cell Biol. 11:44.
15. Hoeflich A, et al. 2001. Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2. Endocrinology 142:1889 -1898.
16. Hoeflich A, et al. 2001. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res. 61:8601- 8610.
17. Imai Y, et al. 2000. Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions. J. Biol. Chem. 275:18188 -18194.
18. Jia G, Mitra AK, Gangahar DM, Agrawal DK. 2009. Regulation of cell cycle entry by PTEN in smooth muscle cell proliferation of human coronary artery bypass conduits. J. Cell. Mol. Med. 13:547-554.
19. Jones JI, Clemmons DR. 1995. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16:3-34.
20. Jones JI, Prevette T, Gockerman A, Clemmons DR. 1996. Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc. Natl. Acad. Sci. U. S. A. 93:2482-2487.
21. Kawai M, et al. 2011. The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton. J. Biol. Chem. 286:14670 -14680.
22. Kiepe D, et al. 2002. Differential effects of insulin-like growth factor binding proteins-1, -2, -3, and -6 on cultured growth plate chondrocytes. Kidney Int. 62:1591-1600.
23. Lieskovska J, Ling Y, Badley-Clarke J, Clemmons DR. 2006. The role of Src kinase in insulin-like growth factor-dependent mitogenic signaling in vascular smooth muscle cells. J. Biol. Chem. 281:25041-25053.
24. Ling Y, Maile LA, Lieskovska J, Badley-Clarke J, Clemmons DR. 2005. Role of SHPS-1 in the regulation of insulin-like growth factor I-stimulated Shc and mitogen-activated protein kinase activation in vascular smooth muscle cells. Mol. Biol. Cell 16:3353-3364.
25. Lu Y, et al. 2003. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J. Biol. Chem. 278:40057- 40066.
26. Maeda N, Noda M. 1998. Involvement of receptor-like protein tyrosine phosphatase zeta/RPTPbeta and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migration. J. Cell Biol. 142:203-216.
27. Maile LA, et al. 2010. A monoclonal antibody against alphaVbeta3 integrin inhibits development of atherosclerotic lesions in diabetic pigs. Sci. Transl. Med. 2:18ra11.
28. Maile LA, et al. 2012. Disruption of the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS)-1 inhibits pathophysiological changes in retinal endothelial function in a rat model of diabetes. Diabetologia 55:835- 844.
29. Mendes KN, Wang GK, Fuller GN, Zhang W. 2010. JNK mediates insulin-like growth factor binding protein 2/integrin alpha5-dependent glioma cell migration. Int. J. Oncol. 37:143-153.
30. Meng K, et al. 2000. Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc. Natl. Acad. Sci. U. S. A. 97:2603-2608.
31. Mitra AK, Jia G, Gangahar DM, Agrawal DK. 2009. Temporal PTEN inactivation causes proliferation of saphenous vein smooth muscle cells of human CABG conduits. J. Cell. Mol. Med. 13:177-187.
32. Nagata Y, et al. 2004. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127.
33. Nam TJ, Busby WH, Jr, Rees C, Clemmons DR. 2000. Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth. Endocrinology 141:1100 -1106.
34. Niu XL, et al. 2007. Leukocyte antigen-related deficiency enhances insulin-like growth factor-1 signaling in vascular smooth muscle cells and promotes neointima formation in response to vascular injury. J. Biol. Chem. 282:19808 -19819.
35. Pariser H, Ezquerra L, Herradon G, Perez-Pinera P, Deuel TF. 2005. Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem. Biophys. Res. Commun. 332:664-669.
36. Pariser H, Herradon G, Ezquerra L, Perez-Pinera P, Deuel TF. 2005. Pleiotrophin regulates serine phosphorylation and the cellular distribution of beta-adducin through activation of protein kinase C. Proc. Natl. Acad. Sci. U. S. A. 102:12407-12412.
37. Parker A, Gockerman A, Busby WH, Clemmons DR. 1995. Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells. Endocrinology 136:2470 -2476.
38. Porzia A, et al. 2010. Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. J. Immunol. 184:4170-4177.
39. Radhakrishnan Y, Busby WH, Jr, Shen X, Maile LA, Clemmons DR. 2010. Insulin-like growth factor-I-stimulated insulin receptor substrate-1 negatively regulates Src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells. J. Biol. Chem. 285:15682-15695.
40. Radhakrishnan Y, Shen X, Maile LA, Xi G, Clemmons DR. 2011. IGF-I stimulates cooperative interaction between the IGF-I receptor and CSK homologous kinase that regulates SHPS-1 phosphorylation in vascular smooth muscle cells. Mol. Endocrinol. 25:1636 -1649.
41. Russo VC, Bach LA, Fosang AJ, Baker NL, Werther GA. 1997. Insulinlike growth factor binding protein-2 binds to cell surface proteoglycans in the rat brain olfactory bulb. Endocrinology 138:4858-4867.
42. Russo VC, et al. 2005. Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 146:4445- 4455.
43. Schütt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW. 2004. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J. Mol. Endocrinol. 32:859-868.
44. Seo JH, Ahn Y, Lee SR, Yeol Yeo C, Chung Hur K. 2005. The major target of the endogenously generated reactive oxygen species in response to insulin stimulation is phosphatase and tensin homolog and not phos-phoinositide-3 kinase (PI-3 kinase) in the PI-3 kinase/Akt pathway. Mol. Biol. Cell 16:348 -357.
45. Shen X, Xi G, Radhakrishnan Y, Clemmons DR. 2009. Identification of novel SHPS-1-associated proteins and their roles in regulation of insulinlike growth factor-dependent responses in vascular smooth muscle cells. Mol. Cell. Proteomics 8:1539 -1551.
46. Shen X, Xi G, Radhakrishnan Y, Clemmons DR. 2010. Recruitment of Pyk2 to SHPS-1 signaling complex is required for IGF-I-dependent mitogenic signaling in vascular smooth muscle cells. Cell. Mol. Life Sci. 67: 3893-3903.
47. Shitara K, Yamada H, Watanabe K, Shimonaka M, Yamaguchi Y. 1994. Brain-specific receptor-type protein-tyrosine phosphatase RPTP beta is a chondroitin sulfate proteoglycan in vivo. J. Biol. Chem. 269:20189 -20193.
48. Snaddon J, Parkinson EK, Craft JA, Bartholomew C, Fulton R. 2001. Detection of functional PTEN lipid phosphatase protein and enzyme activity in squamous cell carcinomas of the head and neck, despite loss of heterozygosity at this locus. Br. J. Cancer 84:1630 -1634.
49. Toker A, Cantley LC. 1997. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387:673- 676.
50. Wood AW, Schlueter PJ, Duan C. 2005. Targeted knockdown of insulinlike growth factor binding protein-2 disrupts cardiovascular development in zebrafish embryos. Mol. Endocrinol. 19:1024 -1034.
51. Wu DN, Pei DS, Wang Q, Zhang GY. 2006. Down-regulation of PTEN by sodium orthovanadate inhibits ASK1 activation via PI3-K/Akt during cerebral ischemia in rat hippocampus. Neurosci. Lett. 404:98 -102.
52. Xi G, Shen X, Clemmons DR. 2008. p66shc negatively regulates insulinlike growth factor I signal transduction via inhibition of p52shc binding to Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 leading to impaired growth factor receptor-bound protein-2 membrane recruitment. Mol. Endocrinol. 22:2162-2175.
53. Xi G, et al. 2012. Hyperglycemia enhances IGF-I-stimulated Src activation via increasing Nox4-derived reactive oxygen species in a PKCzetadependent manner in vascular smooth muscle cells. Diabetes 61:104 -113.
54. Zhang M, et al. 2002. Targeted expression of a protease-resistant IGFBP-4 mutant in smooth muscle of transgenic mice results in IGFBP-4 stabilization and smooth muscle hypotrophy. J. Biol. Chem. 277:21285-21290.